Does administration of clarithromycin prevent pneumonia due to ventilator use?

The effect of clarithromycin in preventing ventilator associated pneumonia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014121620341N1

Enrollment

Registered

2014-12-31

Start date

2013-05-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ventilator-associated pneumonia. Pneumonia, unspecified

Interventions

Intervention: oral clarithromycin 500 mg/BD Control: placebo.

Prevention

Intervention: oral clarithromycin 500 mg/BD Control: placebo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: ICU admission Exclusion criteria: Neutropenia (Absolute Neutrophil Count less than 500 cells/µl); HIV infection; second or three degree atrioventricular (AV) block; Receiving oral corticosteroids in the past month

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pneumonia. Timepoint: 48 hours. Method of measurement: Tracheobronchial smear culture, Colony forming units more than 10000000.	—

Secondary

Measure	Time frame
?APACHI score. Timepoint: day 1, 5, and 10. Method of measurement: physical exam.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Mirjalili

Shahid Sadoughi University of Medical Sciences

dr.mirjalili@ssu.ac.ir+98 35 3725 8771

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026